A Double-blind, Randomised, Placebo-controlled Clinical Trial of the Efficacy of MABp1, a- First-in-class True Human Antibody Targeting Interleukin-1alpha, in Patients With Hidradenitis Suppurativa Not Eligible for antiTNF Therapy
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2017
At a glance
- Drugs MABp1 (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- 07 Sep 2017 Results published in an XBiotech media release.
- 07 Sep 2017 According to an XBiotech media release, results will be presented at the European Academy of Dermatology and Venereology (EADV) Congress 2017.
- 27 Feb 2017 Status changed from active, no longer recruiting to completed.